Dave Windley

Girshick said owning the Mauritius and Cambodia NHP farms lets CRL control quality, logistics and shipment timing and manage capacity to peak demand, a competitive differentiator.

Coleman confirmed the K.F. Cambodia NHP cost benefit is minimal in Q3 and lands mainly in Q4, when DSA margins should move meaningfully higher.

Birgit acknowledged the bar seems conservative but explained other factors beyond book-to-bill affect revenue: study start times (1-2 quarter lag), backlog conversion timing, and non-linear quarterly patterns.

Jim cited improving demand from biotech funding, pharma finishing portfolio rationalization, and tariff concerns easing. Noted shift from post-IND to more general tox work, indicating clients are starting earlier.

Foster said more pre-IND work emerging as biotech clients gain access to capital. Backlogs at 9 months (down from prior highs) allow faster study slotting and quicker revenue conversion, which is positive for near-term growth.

Foster differentiated CRL from competitors experiencing study start delays, saying CRL can start studies quickly given shorter backlog and available capacity, providing flexibility clients need.

Foster declined to identify specific assets being divested, citing the ongoing divestiture process, but confirmed 7% of revenue and $0.30 annualized accretion targets.

Foster said 10-month backlog duration is robust and allows slotting replacement studies for cancellations. Company is performing meaningfully ahead of operating plans and hiring to support demand; pharma has strengthened meaningfully.

Pease confirmed Windley's framing of the CDMO headwind and noted original guidance of about $40 million headwind from two commercial clients; now slightly below 500 basis points impact as one client retains some work.

Pease pushed back on industry reports of price deterioration, saying CRL spot pricing was stable vs Q4 exit rate and Q1 price/mix improvement was driven by favorable study mix, not broad pricing recovery.

Foster quantified direct NIH exposure at 2% of total revenue, broader academic/government at 6%. No adverse impacts from government yet but being cautious in guidance for potential back-half impact.

James confirmed pricing pressure is a continuation not a new intensity, noting they selectively use pricing to gain share but will not match lowest competitors.

James was transparent about maintaining close senior relationships with all major pharma clients and not hearing about a second restructuring wave, while acknowledging some reprioritization continues.

Bob said 200 basis points is well placed with a possibility to accelerate; told analysts to stay tuned.

Eric ranked biologics (NovaPure, FluroTec) highest by ASP and margin, with Annex 1 upgrades on lower-end but still margin-accretive formulations.

Eric expressed pride in the organization and confidence in the executive team. Believes successor will inherit a well-positioned business with clear strategy and aligned global leadership.

Eric confirmed further margin expansion opportunity from NovaPure, Annex-1 conversion, and operational excellence spread to other sites. Bob noted March outperformed January with labor ramp improving, and SmartDose had some margin impact. Second-half operating margins expected to be well above first half.

Eric confirmed demand increasing across all five global HVP plants, with European expansion ongoing. Current investments focused on labor rather than facilities/capital. Bob confirmed tech transfers throughout 2026 to alleviate imbalance.

Bernard cited manufacturing efficiency gains, controlled OpEx spending, and AnnexOne's positive mix shift from standard to HVP margins as offsets.

Eric characterized the changes as natural evolution rather than a strategic reset, expressing appreciation for departing leaders while welcoming new talent.

Management was vague on exact price conversion but Bernard indicated improvement on both price and cost sides, pointing to yield improvements.

Eric identified the integrated prefilled syringe system launch as the largest R&D incremental; SG&A increase is mainly annualization of 2024 hires.

Peter said early adopters are sponsors; service providers have shown interest but Veeva is staying focused on sponsors first.

Peter said Falcon would likely charge by document or safety case, targeting high-volume already-outsourced work first.

Peter acknowledged an air pocket in EDC. Structural advantage with combined clinical operations and data management. eSource initiative is groundbreaking. Late adopters have other priorities. Competitive environment has never been stronger but breakthrough timing hard to predict, could be 1-4 years.

Peter said standardization-for-AI is not yet a broad theme but expects it coming once Veeva AI is proven. Point solutions start failing, and companies need integrated AI, that's when acceleration comes. Promise is there but delivery is hard.

Peter confirmed no restrictions on either party. Open and free market. They will partner in many areas, compete in some, both focused on customer success.

Peter said it is less about new applications and more about pulling through existing ones (Campaign Manager, Service Center, Patient CRM, Network, Nitro, analytics). Products were stalled by Salesforce platform constraints and IQVIA restrictions, both now resolved.

Peter clarified speed to value: combined decision eliminates seven separate RFPs and 18-month independent sales cycles, roughly doubling speed of evaluation.

Brian noted many steps required before any DTC ad ban could take effect and it would likely be challenged. No near-term business impact expected.

Mark clarified the $0.80 below-the-line benefit funds one-time H2 investments and is not part of 2027, while the ~$0.75 of targeted investment spend stays in the run-rate base.

Gail stated willingness to exit unprofitable states but clarified not at that stage currently. Mark added that modestly better 2026 membership would not change 2026 trough-year view, with work requirement impact expected to be phased and manageable.

Felicia confirmed 750,000 member decline is same-store from continued stringent eligibility reverification across states. Mark reconciled with margin: grounded in three assumptions, mid-single-digit cost trend above historical norms, rates improving but lagging, and active use of controllable levers beyond rates.

Mark outlined four drivers for 2027 improvement: tightened medical cost management, phased and manageable OBBBA provisions primarily effective 2027-2028, rates catching up to trend, and intentionally prudent 2026 baseline. Gail added less than 20% of membership impacted by initial OBBBA implementation.

Mark confirmed risk adjustment unchanged because Elevance's mix shifts mirror market-wide deterioration. Assumed ACA membership stability for rest of 2025 but embedded meaningful Q4 utilization surge.

Mark explained flat ASO revenue reflects deliberate shift from fee-based to risk-based contracts in Carelon Services. Felicia noted 70% Medicaid premium visibility with July rates critical.

Sarah said Centene would welcome expanded mandate to operate more aggressively against fraud, noting 30-state data advantage for cross-state fraudulent provider identification. For marketplace 2027, some stayed program integrity measures may see court resolution over summer and could roll forward, being factored into 2027 pricing. Drew noted shortened 2027 open enrollment period.

Sarah noted trade-down to bronze largely consistent with expectations and likely a market-wide dynamic, contemplated in overall pricing. Underwriting incorporated both recent 5-year bronze experience and pre-eAPTC/pre-COVID bronze behavior. January not yet closed but very early utilization data shows nothing alarming.

Sarah disclosed the market likely contracted during 2025 OE and continues shrinking monthly. CNC expects to end 2025 at 5.4M members from 5.9M, with FTR implementation beginning in August files.

Drew confirmed not booking 2025 risk adjustment receivable yet despite seeing diagnosis codes. Sarah noted vast majority of membership is subsidized, consistent with historical mix.

Drew noted broker disruption was addressed in early 2024, CMS adopted their agent-of-record lock idea. Pricing for 2025 includes a load for FTR program integrity measures.

Fedock gave the segment split and Charles River revenue contribution, but Bousbib declined to detail discovery strategy, saying he would leave it at that.

Bruehlman said Q4 gross margin compression driven by very strong pass-through growth and some product mix. Pass-through growth expected to moderate in 2026. Guiding to flat overall EBITDA margins. SG&A margin continues to improve from productivity. Long-term productivity gains shared with clients but near-term repricing at procurement level separate from program-level efficiency.

Bousbib said strength reflects reduced macro uncertainty plus see more win more strategy. Pricing discounts were limited to first half when market was tighter. Q3 saw return to normal pricing with IQVIA walking away from some deals. Impact on P&L immaterial as discounted deals are tiny portion of $32B+ backlog spreading over 5 years.

More margin pressure in R&DS than TAS due to FSP and lab mix. Good SG&A performance in both segments. Cost actions include labor arbitrage, overhead restructuring, and AI agent deployment.

Bousbib cited labor rate optimization across geographies, organizational flattening, IT infrastructure leverage, and accelerated AI tool deployment in internal workflows.